New research indicates a higher risk of neurodevelopmental disorders in children when fathers took valproate three months before conception.
The Medicine and Healthcare products Regulatory Agency (MHRA) in the UK, is closely examining these findings, prompting new safety measures.
Male patients on valproate planning a family within a year should consult healthcare professionals for…
Sorry, this premium content is for RegASK clients only.
Want to access the whole content of the alert or browse all the news?
Subscribe to the latest regulatory news
Curated newsletters
Relevant industry info
Access expert insights
